Atezolizumab received accelerated FDA approval for patients whose disease has progressed despite platinum-based chemotherapy.
Agency is recommending that health care providers not prescribe them for certain patients.
Many believe meds supported by stronger evidence than the law requires to achieve designation.
The diabetes drug was contraindicated due to the risk of lactic acidosis.
Drugs containing saxagliptin or alogliptin may be linked to heart failure risk.
New labeling rules require immediate-release opioids to carry warnings for the serious risk for misuse.
Agency aims to improve treatment of pelvic organ prolapse.
National blood surveillance system will help agency ensure safety of the blood supply.
Drug found to limit worsening of the disease and reduce the need for hospitalization.
Nivolumab is cleared for treating patients with metastatic RCC whose disease advanced despite prior treatment with anti-angiogenic therapy.
Patiromer for oral suspension lowers potassium levels in hyperkalemic patients with chronic kidney disease.
Tresiba and Ryzodeg approved for use in adults with type 1 and 2 diabetes mellitus.
The FDA approved Varubi for prevention of the delayed phase of nausea and vomiting caused by chemotherapy.
FDA advises diabetes patients taking DPP-inhibitors who experience severe joint pain to contact their doctors.
Approved for patients unable to get LDL cholesterol under control with current treatment options.
- CKD Progression After Acute Kidney Injury Characterized
- High Sodium Intake May Up CVD Risk in CKD Patients
- Guidelines Recommend Weight-loss Surgery to Treat Type 2 Diabetes
- Achieving 4 Lifestyle Standards May Reduce Cancer Mortality
- Fluid Overload at RRT Initiation Ups AKI Patients' Long-Term Mortality
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)